Clinical and etiopathogenetic role of plasminogen and metoproteinase systems in the tumor growth pericellular proteolysis of extracellular matrix and tumor growth;klinička ietiopatogenetska uloga plazminogenskoga i metaloproteinaznoga sustava u tumorskome rastu pericelularna razgradnja medustaničnoga matriksa i tumorski rast

Lijecnicki Vjesnik

Volumn 133, Issue 1-2, 2011, Pages 56-63

  Ćosić, Sanda Jelisavac ^a   Kovač, Zdenko ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Analysis; Biological Analysis; Breast neoplasms Diagnosis; Extracellular matrix Metabolism; Matrix metalloproteinases Metabolism; Neoplasm metastasis Physiopathology; Neoplasms Metabolism; Pathology; Plasminogen activator inhibitor 1 Metabolism; Tissue plasminogen activator Metabolism; Tumor markers; Urokinase type plasminogen activator Metabolism

Indexed keywords

METALLOPROTEINASE; PLASMINOGEN; PLASMINOGEN ACTIVATOR;

ANIMAL; EXTRACELLULAR MATRIX; HUMAN; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; EXTRACELLULAR MATRIX; HUMANS; METALLOPROTEASES; NEOPLASMS; PLASMINOGEN; PLASMINOGEN ACTIVATORS;

EID: 79957509621     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Tabrruyn SP, Griffioen AW. Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun 2007;355:1-5 (Pubitemid 46273381)
2. Ingber DE. Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circ Res 2002;91:877-87. (Pubitemid 35373587)
3. Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol 2007;26:587-96. (Pubitemid 350180394)
4. Adibhalia RM, Hatcher J. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: Therapeutic strategies. CNS Neurol Disorder Drug Targets 2008;7:243-53.
5. Overall CM, Dean RA. Degradomics: Systems biology of me protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev 2006; 25:69-75. (Pubitemid 43723983)
6. Dass K, Ahmad A, Azmi SA, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancer. Cancer Treatment Rev 2008;34: 122-36.
7. Duffy MJ. The urokinase activator system. Role in malignancy. Curr Pharm Res 2004;10:39-49. (Pubitemid 38072742)
8. Cunningham O, Andolfo A, Sanlovilo ML, Iuzollino L, Blasi F, Sidenius N. Dimerization controls me lipid raft partitioning of UPAR/CD87 and regulates its biological functions. EMBO J 2003;22:5994-6003. (Pubitemid 37463243)
9. Longslaff C, Williams S, Thelwll C. Fibrin binding and the regulation od plasminogen activators during thrombolytic dierapy. Cardiovasc Hematol Agents Med Chem 2008;6:212-23.
10. Yarovaya GA, Blokhina TB, Neshkova EA. Contact system. New concepts of activation mechanisms and bioregulatory functions. Biochemistry (Mose) 2002;67:13-24.
11. Rha SJ, Yang WI, Gong SJ i sur. Correlation of tissue and blood plasminogen activation system in breast cancer. Cancer- Lett 2000; 150: 137-45. (Pubitemid 30125847)
12. Coughlin PB. Antiplasmin. The forgotten serpin. FEBS J 2005;272: 4852-7.
13. Loskutoff DJ, Sewdey M, Mimuro J. Type-1 plasminogen activator inhibitor. U: Coller BS, ur. Progress in hemostasis and thrombosis. Philadelphia: Saunders; 1989, str. 87-115.
14. Noël A, Bajou K, Masson Vi sur. Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1. Fibrinolysis & Proteolysis 1999; 13(6):220-25.
15. Czekay RP, Aertgeerts K, Curriden SA, Lokustoff DJ. Plasminogen activator inhibitor-1 detectes cells from extracellular matrices by inactivating integrins. J Cell Biol 2003;160(5):781-91. (Pubitemid 36298272)
16. Rosenthal EL, Matrisian LM. Matrix metalloproteases in head and neck cancer. Head Neck-Doi 10.1002/hed 639-48.
17. Kovač Z. Nestabilnost genoma i poremećaj staničnoga ciklusa u karcinogenezi. U: Gamulin S, Marušić M i Kovač Z, ur. Patofiziologija, 6. izd. Zagreb: Medicinska naklada; 2005, str. 626-30.
18. Wahl ML, Kenan DJ, Gonzales-Gronow M, Pizzo SV. Angiostatin'smolecular mechanisms: Aspects of specificity and regulation elucidiated. J Cell Biochem 2005;96:242-6.
19. O 'Reilly MS. Boehm T, Shing Y i sur. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
20. Hammano Y, Kullari R. Tumstatin, the NC1 domain of alpha 3 chain of type IV collagen is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem Biophys Res Commun 2005;333:292-8.
21. Chiarugi P, Giannoni E. Anoikis: A necessary death program for anchorage dependent cells. Biochem Pharmacol 2008;26:1552-64.
22. Eccles SA, Weich DR. Metastasis: Recent discoveries and novel treatment strategies. Lancet 2007;369:1742-57. (Pubitemid 46755391)
23. Lock R, Debnath J. Extracellular matrix regulation of autophagy. Curr Opin Cell Biolog 2008;20:583-8.
24. Gupta A, Lotan Y, Ashfag R i sur. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol 2008, doi 10.10167j.eurouro.2008.06.054.
25. Laiho M, Keski-Oja J. Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res 1989;49:2533-2553. (Pubitemid 19143375)
26. Irigoyen JP, Muñoz-Cánoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: biology and regulation. Cell MoI Life Sci 1999;56:104-32. (Pubitemid 29471930)
27. Steiner E, Pollow K, Hasenclever D i sur. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer. Gyn Oncol 2008;108:569-76.
28. Schmitt M, Mengele K, Schueren E i sur. European organisation for research and treatment of cancer (EORTC) pathobiology group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers. Eur J Cancer 2007;43:835-844. (Pubitemid 46366694)
29. Jelisavac Ćosić S. Urokinazni i tkivni aktivator plazminogena i njihov inhibitor (PAI-1) u raku dojke (Magistarski rad). Zagreb: Farmaceutsko-biokemijski fakultet Sveučilišta u Zagrebu; 2004, str. 50.
30. Sobel BE. Increased plasminogen activator inhibitor-1 vasculopathy. A reconciable paradox. Circulation 1999;99:2496-8. (Pubitemid 29228277)
31. Overall CM, Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 2006;94:941-6.
32. Kovač Z, Gamulin S. Cjelovito reagiranje suprotstavljenih regulacijskih menanizama. U: Gamulin S, Marušić M i Kovač Z, ur. Patofiziologija, 6. izd. Zagreb: Medicinska naklada; 2005, str. 540-1.
33. Fitzgibbons PL, Page DL, Weaver D. Prognostic factors in breast cancer (College of American pathologists consensus statement 1999). Arch Pathol Lab Med 2000;124:966-78.
34. Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002;48(8):1194-97. (Pubitemid 34809824)
35. Look MP, van Putten WU, Duffy MJ i sur. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2000;94:116-28. (Pubitemid 34121291)
36. Janicke F, Prechtl A, Thomssen C i sur. Randomized adjuvant chemotherpy trial in high-risk node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. German Chemo N0 Study Group. J Natl Cancer Inst 2001;93:913-20. (Pubitemid 32624648)
37. Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002;48(8): 1194-97. (Pubitemid 34809824)
38. Hayes DF, Bast RC, Desch CEi sur. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66. (Pubitemid 26340047)
39. Harbeck N, Kates RE. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3424). Clin Chem 2002;62:4617-22.
40. Duffy MJ, Duggan C, Mulcahly HE, McDermott EW, O'Higgins NJ. Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease. Clin Chem 1998;44:1177-83. (Pubitemid 28283054)
41. Look MP, van Putten WL, Duffy MJ i sur. Pooled analysis of prognostic impact of urokinase plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94:116-28. (Pubitemid 34121291)
42. Sillfried GE, Saunders DN, Ranson M. Plasminogen binding and activation at the breast cell surface: the integral role or urokinase activity. Breast Cancer Res 2007;9.R14-18.
43. Castello T, Espana F, Vazquez C, Almenar SM, Aznmar J. Plasminogen activator inhibitor-1-4G/5G polymorphism in breast cancer patient and its association with tissue PAI-1 levels and tumor severity. Thromb Res 2006;117:487-92. (Pubitemid 43326132)
44. Shanat SF, Roehrborn CG, McConnel JD i sur. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007;25:349-55. (Pubitemid 350002982)
45. Shiomi H, Eguchi Y, Tani T, Kodama M, Hattori T. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am J Pathol 2000;156:567-75. (Pubitemid 30643812)
46. Ji F, Chen YL, Wang WL, Yang ZL, LiMW. Relationship between matrix metalloproteinase-1 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer. World J Gastroenterol 2005;11:3222-6. (Pubitemid 40973889)
47. Zhang L, Zhao ZS, Ru GQ, Ma J. Correlation studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. World J Gastroenterol 2005;12:3970-6. (Pubitemid 44097102)
48. Binder BR. Mihaly J. The plasminogen activator inhibitor "paradox" in cancer. Immunol Lett 2008; 118:116-24.
49. Nielsen HJ, Christensen IJ, Sorensen S, Moesgard E, Brunner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum Creactive protein levels in patients with colorectal cancer. The TANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2000;7:617-23.
50. Hogdall CK, Christensen IJ, Stephens RW, Sorensen-Pedersen B, Nielsen HJ. Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-I and serum CEA, APMIS 2002; 110:630-8. (Pubitemid 35335132)
51. Tsuchiya H, Sunayama C, Matsuda E, Tomita K, Binder BR. Plasminogen activator inhibitor-1 accelerates lung metastasis formation of human fibrosarcoma cells. Anticancer Res 1997;313-6. (Pubitemid 27116685)
52. Baker EA, Leaper DJK. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumor pathology. Eur J Cancer 2003;39:981-8. (Pubitemid 36428631)
53. McCawley LJ, Matrisian LM. Matrix metalloproteinases: They are not just for matrix anymore. Curr Opin Cell Biol 2001;13:534-40. (Pubitemid 32817010)
54. Mastroianni C. Liuzzi GM. Matrix metalloproteinase dysregulation in HIV infection: Implications for therapeutic strategies. Trends Mol Med 2007;13:449-59. (Pubitemid 350086978)
55. Imaik, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation of decorin by matrix metalloproteinases: Identification of cleveage sites, kinetic analysis and transforming growth factor-beta 1 release. Biochem J 1997;269:809-14. (Pubitemid 27135628)
56. Foekens JA, Peters HA. Look MP. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60:636-43. (Pubitemid 30094561)